Histology and Cytology Market Size is expected to be significantly augmented owing to the rising cancer burden worldwide. According to the World Health Organization estimates, cancer is one of the leading causes of death worldwide and was responsible for an estimated 10 million fatalities in 2020. An increase in demand for diagnosis of cancer cells and several other cell-based diseases would well-escalate the market prospects over the span of 2022 to 2028.
Histology and cytology are the study of tissues and cells respectively, which allows various medical and healthcare professionals to determine the underlying diseases and deformities through tissue and cell diagnosis.
Technological advancements in cell and tissue diagnosis, along with the ongoing research and development activities in the space are also likely to support histology and cytology market demands in the coming years. For instance, researchers at the UCLA Samueli School of Engineering and the David Geffen School of Medicine, recently, announced creating a novel virtual histology technology that can reduce the need for skin biopsies.
Increases cost associated with histology tests is anticipated to hamper the market growth statistics during the analysis period. However, growing number of well-equipped clinical laboratories and favorable reimbursement policies for cancer screening and tests across different underdeveloped regions would open new growth avenues for the market expansion.
Based on the examination type, cytology segment is predicted to account for considerable growth in the ensuing years. This can be ascribed to the rising demand for cytology examination for the prevention and diagnosis of various tissue and cell diseases. Some of the robust advantages associated with the use of cytological examination are that it is safe, cost effective, simple, and offers quick results. The main application of this is to carry out specimen samples for diagnosing different cancers like breast cancer, cervical cancer, and others. This would imply that the increasing prevalence of breast cancers would enhance the cytology segment size across histology and cytology market through 2028. In 2020, the world recorded nearly 2.3 million breast cancer cases and about 685,000 fatalities globally.
Hospitals and clinics are projected to account for notable gains in the overall histology and cytology market due to the growing ingress of cancer patients and patients with other cell and tissue deformities in hospitals and clinics. Besides, factors like higher purchasing power, well-resourced diagnostic rooms, improved health coverage for hospital-based healthcare services and highly skilled healthcare professionals, would as well complement the segmental growth.
Regionally, North America histology and cytology market would foresee significant growth over 2022-2028 subject to the high incidences of cancer, widening R&D activities, presence of prominent players, and established research infrastructure for pathology services. As per credible estimates, it was reported that nearly 1.9 million people would be diagnosed with cancer in the United States by 2021 end, with approximately 281,550 women being diagnosed with breast cancer. Additionally, high rate of product approval and commercialization of histology and cytology examination services in the region is as well contributing to the regional market growth.
Companies operating in the global histology and cytology market, including Abbott Laboratories, F. Hoffmann-La Roche, Becton Dickinson & Company, Thermo Fisher Scientific, Merck and Co., Danaher Corporation, Sysmex Corporation, and others, are taking up strategic marketing efforts like M&A, partnerships, and product launches to fortify their position in the overall market space.
Although the COVID-19 crisis escalated the research and development activities worldwide regarding mitigating the spread of the infection, it has brought to standstill various businesses and industries, even across the healthcare industry. One of them was histology and cytology market. this can be reasoned to the shifting interest of various clinical institutes to development and studies of potential treatments for COVID-19.
Market, by Examination Type
Market, by Test Type
Market, by End-use
The above information is provided for the following regions and countries: